EXAMINE-HCM

Authors: Ethan J. Rowin, MD, Gaurav Das, MD, Christopher Madias, MD, Mike Hsu, PhD, Lori Crosson, PhD, Mintu P. Turakhia, MD, MAS, Barry J. Maron, MD, Martin S. Maron, MD.

Summary:

A single-center prospective study of 236 adults with hypertrophic cardiomyopathy used a 14-day continuous ambulatory ECG patch (Zio XT) to compare non-sustained VT detection during the initial 48 hours versus the full two-week period and examined how extended monitoring might influence ESC sudden-death risk stratification.

Key Findings:

Only 37% of NSVT cases were detected within the first 48 hours.

14-day monitoring increased NSVT diagnostic yield by 2.7x.

ESC sudden-death risk up-classification in ~17% of patients.

"High-risk" VT detection (≥8 beats, >200 bpm, or ≥2 runs in a consecutive 2-day period) tripled with extended monitoring.

The content on iRhythm Academy is provided for general educational purposes only and should not be considered the exclusive source for this type of information. This training does not replace or supersede approved labeling. The content will be shared with physicians and healthcare professionals who seek a deeper understanding of the operation and use of iRhythm products and services with the intent of enhancing their knowledge of features and operations described in the clinician manuals. At all times, it is the professional responsibility of the physicians and healthcare professionals to exercise independent clinical judgment in a particular situation. The device and service functionality and programming described on iRhythm Academy are based on its products and services, and can be referenced in the labeling and reference manuals. This website is intended for healthcare professionals and not intended for patients or consumers.